BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company…
Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and…
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company…
Biomaterial catheters help avoid common vascular access complications, delivering improved patient outcomes and a lower cost of careBILLERICA, Mass., Dec.…
SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that…
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety…
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene…
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in…
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with…
-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in…